CLINICAL TRIALS PROFILE FOR NEXTERONE
✉ Email this page to a colleague
All Clinical Trials for NEXTERONE
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT01401647 ↗ | Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia | Completed | American Heart Association | Phase 3 | 2012-05-01 | The primary objective of the trial is to determine if survival to hospital discharge is improved with early therapeutic administration of a new Captisol-Enabled formulation of IV amiodarone (Nexterone-PM101) compared to placebo. |
NCT01401647 ↗ | Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia | Completed | Canadian Institutes of Health Research (CIHR) | Phase 3 | 2012-05-01 | The primary objective of the trial is to determine if survival to hospital discharge is improved with early therapeutic administration of a new Captisol-Enabled formulation of IV amiodarone (Nexterone-PM101) compared to placebo. |
NCT01401647 ↗ | Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia | Completed | Defence Research and Development Canada | Phase 3 | 2012-05-01 | The primary objective of the trial is to determine if survival to hospital discharge is improved with early therapeutic administration of a new Captisol-Enabled formulation of IV amiodarone (Nexterone-PM101) compared to placebo. |
NCT01401647 ↗ | Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia | Completed | Heart and Stroke Foundation of Canada | Phase 3 | 2012-05-01 | The primary objective of the trial is to determine if survival to hospital discharge is improved with early therapeutic administration of a new Captisol-Enabled formulation of IV amiodarone (Nexterone-PM101) compared to placebo. |
NCT01401647 ↗ | Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | 2012-05-01 | The primary objective of the trial is to determine if survival to hospital discharge is improved with early therapeutic administration of a new Captisol-Enabled formulation of IV amiodarone (Nexterone-PM101) compared to placebo. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for NEXTERONE
Condition Name
Clinical Trial Locations for NEXTERONE
Trials by Country
Clinical Trial Progress for NEXTERONE
Clinical Trial Phase
Clinical Trial Sponsors for NEXTERONE
Sponsor Name
Sponsor Name for NEXTERONE | |
Sponsor | Trials |
National Heart, Lung, and Blood Institute (NHLBI) | 1 |
U.S. Army Medical Research and Development Command | 1 |
U.S. Army Medical Research and Materiel Command | 1 |
[disabled in preview] | 2 |
This preview shows a limited data set Subscribe for full access, or try a Trial |